Adenosine
- Generic Name
- Adenosine
- Brand Names
- Adenocard, Viva-drops Lubricating Eye Drops
- Drug Type
- Small Molecule
- Chemical Formula
- C10H13N5O4
- CAS Number
- 58-61-7
- Unique Ingredient Identifier
- K72T3FS567
- Background
The structure of adenosine was first described in 1931, though the vasodilating effects were not described in literature until the 1940s. Adenosine is indicated as an adjunct to thallium-201 in myocardial perfusion scintigraphy, though it is rarely used in this indication, having largely been replaced by dipyridamole and [regadenson]. Adenosine is also indicated in the treatment of supraventricular tachycardia.
Adenosine was granted FDA approval on 30 October 1989.
- Indication
Adenosine is indicated as an adjunct to thallium-201 in myocardial perfusion scintigraphy in patients unable to adequately exercise. It is also indicated to convert sinus rhythm of paroxysmal supraventricular tachycardia.
- Associated Conditions
- Paroxysmal Supraventricular Tachycardia (PSVT), Pulmonary Arterial Hypertension (PAH), SVT, Supraventricular Tachycardia (SVT)
Effects of REnal Denervation for Resistant Hypertension on Exercise Diastolic Function and Regression of Atherosclerosis and the Evaluation of NEW Methods Predicting A successfuL Renal Sympathetic Denervation (RENEWAL-EXERCISE, -REGRESS, and -PREDICT Trial From RENEWAL RDN Registry)
- Conditions
- Resistant Hypertension
- Interventions
- Procedure: Renal denervation
- First Posted Date
- 2013-08-07
- Last Posted Date
- 2019-03-28
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 16
- Registration Number
- NCT01918111
- Locations
- 🇰🇷
Severance hospital, Seoul, Korea, Republic of
Cardiac Safety Study in Patients With HER2 + Breast Cancer
- Conditions
- HER2 Positive Breast CancerLeft Ventricular Function Systolic Dysfunction
- Interventions
- First Posted Date
- 2013-07-22
- Last Posted Date
- 2022-05-10
- Lead Sponsor
- Medstar Health Research Institute
- Target Recruit Count
- 31
- Registration Number
- NCT01904903
- Locations
- 🇺🇸
Washington Cancer Institute at MedStar Washington Hospital Center, Washington, District of Columbia, United States
🇺🇸MedStar Georgetown University Hospital, Washington, District of Columbia, United States
Regadenoson and Adenosine
- Conditions
- Coronary Artery Disease
- Interventions
- First Posted Date
- 2013-03-13
- Last Posted Date
- 2013-11-13
- Lead Sponsor
- Lokien van Nunen
- Target Recruit Count
- 100
- Registration Number
- NCT01809743
- Locations
- 🇳🇱
Catharina Hospital, Eindhoven, Noord-Brabant, Netherlands
REperfusion Facilitated by LOcal Adjunctive Therapy in ST-elevation Myocardial Infarction
- Conditions
- ST-elevation Myocardial Infarction (STEMI)
- Interventions
- First Posted Date
- 2012-12-11
- Last Posted Date
- 2015-06-16
- Lead Sponsor
- University Hospitals, Leicester
- Target Recruit Count
- 247
- Registration Number
- NCT01747174
- Locations
- 🇬🇧
Glenfield Hospital, Leicester, Leicestershire, United Kingdom
🇬🇧University Hospital, Coventry, West Midlands, United Kingdom
🇬🇧Freeman Hospital, Newcastle upon Tyne, Tyne and Wear, United Kingdom
Effect of Ticagrelor vs. Dipyridamole on Adenosine Uptake
- First Posted Date
- 2012-09-24
- Last Posted Date
- 2018-02-28
- Lead Sponsor
- Vanderbilt University
- Target Recruit Count
- 28
- Registration Number
- NCT01690884
- Locations
- 🇺🇸
Autonomic Dysfunction Center, Nashville, Tennessee, United States
Phase II Study for the Diagnosis and Functional Assessment of CAD Using Transthoracic-Echodoppler
- First Posted Date
- 2012-05-08
- Last Posted Date
- 2012-09-07
- Lead Sponsor
- Adenobio N.V
- Target Recruit Count
- 75
- Registration Number
- NCT01593644
- Locations
- 🇫🇷
Centre Hospitalier de Compiègne, Compiègne, France
Validation Durability Adenosine Effect in Verification Pulmonary Vein Isolation
- First Posted Date
- 2012-05-03
- Last Posted Date
- 2017-11-06
- Lead Sponsor
- Medical College of Wisconsin
- Target Recruit Count
- 20
- Registration Number
- NCT01590875
- Locations
- 🇺🇸
Froedtert Hospital, Milwaukee, Wisconsin, United States
Dexmedetomidine and Adenosine: Therapeutic Use for SVT
- Conditions
- Supraventricular Tachycardia
- Interventions
- First Posted Date
- 2011-12-20
- Last Posted Date
- 2017-03-28
- Lead Sponsor
- University of Pittsburgh
- Target Recruit Count
- 22
- Registration Number
- NCT01495481
- Locations
- 🇺🇸
Childrens Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States
Myocardial Blood Flow by PET and N-13 Ammonia During Regadenoson vs Adenosine Stress
- Conditions
- Coronary Artery Disease
- Interventions
- First Posted Date
- 2011-06-09
- Last Posted Date
- 2013-09-05
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 12
- Registration Number
- NCT01370265
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Study of the Safety and Efficacy of Apadenoson for Detection of Myocardial Perfusion Defects Using SPECT MPI
- Conditions
- Coronary Artery Disease
- Interventions
- First Posted Date
- 2011-03-11
- Last Posted Date
- 2012-05-01
- Lead Sponsor
- Forest Laboratories
- Target Recruit Count
- 197
- Registration Number
- NCT01313572
- Locations
- 🇺🇸
Forest Investigative Site 162, New Brunswick, New Jersey, United States
🇺🇸Forest Investigative Site 143, Melbourne, Florida, United States
🇧🇷Forest Investigative Site 308, Belo Horizonte, Brazil
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.